Sarah Sammons, Co-Leader of Breast Oncology at UMGCCC, shared on X:
“Second reportedly negative upfront SERD trial in ER+ HER2- MBC negative. ESR1 mutation still reigns as biomarker for SERDs in advanced disease.
Update on SERENA-4 Phase III trial of Etcamah in combination with palbociclib in upfront 1st-line advanced ER-positive breast cancer.”
You can also read:
